一例 HER2 基因突变的非小细胞肺癌患者在药物诱发间质性肺病后成功再次使用曲妥珠单抗德鲁西康：病例报告

IF 3 Q2 ONCOLOGY

JTO Clinical and Research Reports Pub Date : 2023-12-26 DOI:10.1016/j.jtocrr.2023.100628

Sangho Nam MD , Sun Min Lim MD, PhD , Byoung Chul Cho MD, PhD , Jii Bum Lee MD

{"title":"一例 HER2 基因突变的非小细胞肺癌患者在药物诱发间质性肺病后成功再次使用曲妥珠单抗德鲁西康：病例报告","authors":"Sangho Nam MD , Sun Min Lim MD, PhD , Byoung Chul Cho MD, PhD , Jii Bum Lee MD","doi":"10.1016/j.jtocrr.2023.100628","DOIUrl":null,"url":null,"abstract":"<div><p>Trastuzumab deruxtecan, an antibody-drug conjugate targetingHER2-expressing tumor cells, was found to have promising results in treatment-refractory, metastatic NSCLC harboring <em>HER2</em> mutations. Nevertheless, drug-induced interstitial lung disease (ILD)/pneumonitis is a concern that limits treatment response in this subset of patients. For grade 2 or more ILD/pneumonitis, permanent discontinuation is warranted with vigorous treatment with high-dose steroid. We report a case of successful rechallenge of trastuzumab deruxtecan after recovery of grade 3 ILD/pneumonitis in treatment-refractory NSCLC harboring <em>ERBB2</em> Y772-A775dup.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364323001716/pdfft?md5=aa062d963526168862c30d4691ed7ca4&pid=1-s2.0-S2666364323001716-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case Report\",\"authors\":\"Sangho Nam MD , Sun Min Lim MD, PhD , Byoung Chul Cho MD, PhD , Jii Bum Lee MD\",\"doi\":\"10.1016/j.jtocrr.2023.100628\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Trastuzumab deruxtecan, an antibody-drug conjugate targetingHER2-expressing tumor cells, was found to have promising results in treatment-refractory, metastatic NSCLC harboring <em>HER2</em> mutations. Nevertheless, drug-induced interstitial lung disease (ILD)/pneumonitis is a concern that limits treatment response in this subset of patients. For grade 2 or more ILD/pneumonitis, permanent discontinuation is warranted with vigorous treatment with high-dose steroid. We report a case of successful rechallenge of trastuzumab deruxtecan after recovery of grade 3 ILD/pneumonitis in treatment-refractory NSCLC harboring <em>ERBB2</em> Y772-A775dup.</p></div>\",\"PeriodicalId\":17675,\"journal\":{\"name\":\"JTO Clinical and Research Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2023-12-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666364323001716/pdfft?md5=aa062d963526168862c30d4691ed7ca4&pid=1-s2.0-S2666364323001716-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JTO Clinical and Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666364323001716\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364323001716","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

曲妥珠单抗德鲁司坦是一种靶向表达 HER2 的肿瘤细胞的抗体药物共轭物，在治疗难治性、携带 HER2 突变的转移性 NSCLC 方面取得了良好的效果。然而，药物诱发的间质性肺病（ILD）/肺炎是一个令人担忧的问题，它限制了这部分患者的治疗反应。对于 2 级或 2 级以上的间质性肺病/肺炎，需要永久停药并使用大剂量类固醇进行积极治疗。我们报告了一例携带ERBB2 Y772-A775dup的难治性NSCLC患者在3级ILD/肺炎痊愈后成功重新接受曲妥珠单抗德鲁司坦治疗的病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case Report

Trastuzumab deruxtecan, an antibody-drug conjugate targetingHER2-expressing tumor cells, was found to have promising results in treatment-refractory, metastatic NSCLC harboring HER2 mutations. Nevertheless, drug-induced interstitial lung disease (ILD)/pneumonitis is a concern that limits treatment response in this subset of patients. For grade 2 or more ILD/pneumonitis, permanent discontinuation is warranted with vigorous treatment with high-dose steroid. We report a case of successful rechallenge of trastuzumab deruxtecan after recovery of grade 3 ILD/pneumonitis in treatment-refractory NSCLC harboring ERBB2 Y772-A775dup.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

JTO Clinical and Research Reports Medicine-Oncology

CiteScore

4.20

自引率

0.00%

发文量

145

审稿时长

19 weeks